Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | REGN7945 |
| Synonyms | |
| Therapy Description |
REGN7945 is a bispecific antibody that targets CD38 and CD28, which potentially increases T-cell activation and cytotoxicity against tumor cells (Blood (2024) 144 (Supplement 1): 3283). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| REGN7945 | REGN-7945|REGN 7945 | CD28 Antibody 12 CD38 Antibody 21 | REGN7945 is a bispecific antibody that targets CD38 and CD28, which potentially increases T-cell activation and cytotoxicity against tumor cells (Blood (2024) 144 (Supplement 1): 3283). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|